8 citations
,
October 2021 in “Stem Cell Research & Therapy” Mesenchymal stem cells may effectively treat and prevent allergic skin conditions.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
4 citations
,
January 2025 in “Dermatologica Sinica” Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.
October 2025 in “Journal of Advanced Trends in Medical Research” Rosemary shows promise in treating alopecia, similar to minoxidil, but more research is needed.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
May 2025 in “Acta Dermato Venereologica” Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
2 citations
,
January 2013 in “International Journal of Dermatology” ALDOA levels drop in hair cells during hair loss.
1 citations
,
July 2024 in “PharmacoEconomics - Open” The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
April 2025 in “Dermatology and Therapy” Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
July 2022 in “International journal of KIU” Genetics influence opioid addiction risk, diet affects COVID-19 severity, Aerva lanata may harm kidneys, some plants fight fungi and cancer, and nursing students need better contraceptive knowledge.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
195 citations
,
June 2005 in “American Journal of Human Genetics” Genetic variation in the androgen receptor gene mainly causes early-onset hair loss, with maternal inheritance playing a key role.
4 citations
,
March 2024 in “Quality of Life Research” More severe hair loss in alopecia areata greatly impacts patients and caregivers.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
22 citations
,
November 2021 in “Dermatology and Therapy” The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
April 2026 in “BMC Biotechnology” Curcumin spanlastics are the most effective for cancer therapy due to their strong antimicrobial, antioxidant, and antitumor effects.
February 2026 in “Journal of Integrative Neuroscience” NGF-modified hair follicle stem cells may help treat Alzheimer's by improving brain function and reducing harmful proteins.